2408 316

Cited 0 times in

당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제

Other Titles
 Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist 
Authors
 이인국  ;  강은석 
Citation
 Journal of Korean Diabetes, Vol.20(3) : 149-156, 2019 
Journal Title
Journal of Korean Diabetes
ISSN
 2233-7431 
Issue Date
2019
Keywords
Cardiovascular diseases ; Diabetes mellitus ; Glucagon-like peptide-1 ; Kidney diseases ; Obesity
Abstract
According to the American Diabetes Association (ADA) and the European Association for the Study
of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-
1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease.
This recommendation is based on the results of recent cardiovascular outcome trials of this kind of
medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of
hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular
events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal
stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement
in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed
efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established
cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.
Files in This Item:
T201904427.pdf Download
DOI
10.4093/jkd.2019.20.3.149
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Lee, Inkuk(이인국)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/173278
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links